Canopy Biosciences Acquired by Bruker After 4 Years As BioGenerator Incubated Startup
EQ IQ- 2 Min Read
367 Views- Visitors
In order to offer transparency into how our stories are produced and to teach our readers about the importance of media literacy online, EQ's editorial team provides a quick self-rating of the integrity of the articles and the facts presented against the following EQ IQ metrics.
- Edited by EQ
- Submitted by BioSTL Press Release
Canopy Biosciences has been acquired by publicly-traded multi-national, Bruker. Canopy will continue to build its multi-omics and imaging business from its St. Louis HQ from inside The BioSTL Building.
Canopy Biosciences, a commercial stage multi-omics and fluorescent imaging business, was acquired by Bruker Corporatio of Billerica, Massachusetts. Financial details were not disclosed.
Canopy will remain based in the The BioSTL Building, focusing on gene editing and expression analysis. The company seeks out advanced technologies for commercialization of high-tech products and services in the research tools space.
Compared to a therapeutic or medical device, research tools have minimal development time and minimal regulatory risk. To fuel growth, Canopy previously acquired Zellkraftwerk (Germany) and Core Diagnostics (California), expanding into ChipCytometry and CLIA clinical services.
“This is an important milestone for Canopy and the St. Louis startup ecosystem,” said Edward Weinstein, PhD, co-founder and CEO of Canopy Biosciences. “Bruker is an industry leader with global sales and marketing, which, as our new parent company, will enable continued expansion of Canopy’s business.”
Canopy was founded by BioGenerator in late 2016. The company was founded by then BioGenerator Entrepreneurs in Residence, Weinstein and David Smoller, along with Crystal Winkeler, then a BioGenerator Senior Investment Analyst.
BioGenerator led Canopy’s seed financing round in 2017, which was followed by a Series A in 2018 led by BioGenerator and Kingdom Capital. In 2019, Canopy raised a Series B round led by Ampersand Capital Partners, using the proceeds for the acquisitions of Zellkraftwerk and Core Diagnostics. Additional Canopy investors include St. Louis Arch Angels, Pinpoint Holdings, Synchrony Bio, Missouri Technology Corporation, and other angel investors.
“In the current challenging environment for companies in this sector, we are pleased to join forces with a market leader that has the necessary resources to advance Canopy’s business,” said Charlie Bolten, BioGenerator Senior Vice President. “BioGenerator’s investment returns from Canopy will be redeployed into several innovative new St. Louis ventures being launched in strong markets such as health care data analytics, remote patient care and monitoring, and specific areas within therapeutics.”
Canopy has grown quickly since receiving investment from BioGenerator, angel investors, and the founders in late 2016, reaching 50 total employees led from the Company’s St. Louis headquarters at the BioGenerator Labs inside The BioSTL Building. The company also has operations in Hayward, California and in Hannover and Leipzig, Germany.
“Canopy’s success is a testament to BioGenerator’s innovative collection of programs designed to help St. Louis startups thrive,” said Eric Gulve, PhD, BioGenerator President. “Our initiatives to recruit and support highly talented individuals, provide access to early-stage risk capital, and minimize barriers to accessing high quality laboratory space were all brought to bear in the creation of Canopy Biosciences.”
“The addition of Bruker, a multi-national, publicly-traded company with a 60-year history, to the community of scientists, entrepreneurs, and startups in The BioSTL Building is a milestone for the St. Louis life sciences ecosystem,” said Donn Rubin, President and CEO of BioSTL and Chairman of BioGenerator. “Bruker’s acquisition of Canopy is another proofpoint that St. Louis’ rich talent and innovation are a magnet for national investment.”